sutthirat sutthisumdang Piper Sandler has initiated coverage of Tempus AI ( NASDAQ: TEM ) with a neutral rating, commenting that valuation was keeping it on the sidelines. While it sees Tempus as having a “respectable market position in profiling and leading the pack in data and pharma services,” Piper said it would like to see more revenue generation before giving it a top industry multiple. “The stock is trading between Natera ( NTRA ) and Guardant Health ( GH ), which we think is exactly right, so we think the risk/reward is balanced from here,” Piper said in a note.
The investment bank set its price target for the stock at $40. More on Tempus AI Earnings Season Launches With Delta, PepsiCo, JPMorgan, And Citi Leading Off Tempus AI: Healthcare AI Play Faces Some Challenges From The Start Spotlight On Apple's AI Strategy, The Fed Meeting, And Latest CPI Print Tempus AI GAAP EPS of -$6.86 misses by $3.
53, revenue of $165.97M beats by $5.67M Tempus AI down despite bullish starts from analysts.
